Literature DB >> 31753437

Anatomical and Procedural Factors of Severe Pulmonary Vein Stenosis After Cryoballoon Pulmonary Vein Ablation.

Kenichi Tokutake1, Michifumi Tokuda1, Seigo Yamashita1, Hidenori Sato1, Hirotsugu Ikewaki1, Eri Okajima1, Hirotsuna Oseto1, Masaaki Yokoyama1, Ryota Isogai1, Kenichi Yokoyama1, Mika Kato1, Ryohsuke Narui1, Shinichi Tanigawa1, Seiichiro Matsuo1, Satoru Miyanaga1, Kenichi Sugimoto1, Michihiro Yoshimura1, Teiichi Yamane2.   

Abstract

OBJECTIVES: This study examined the anatomical or procedural factors associated with severe pulmonary vein (PV) stenosis after cryoballoon PV isolation.
BACKGROUND: PV stenosis is a complication associated with cryoballoon ablation.
METHODS: The study included 170 consecutive patients with paroxysmal atrial fibrillation who underwent cryoballoon ablation. In addition to factors generally considered to be related to the occurrence of PV stenosis (PV size, cryoballoon application number and time, and minimum freezing temperature), we evaluated the following 4 factors: 1) depth of balloon position; 2) the PV angle (internal angle between each PV and horizontal line); 3) noncoaxial balloon placement (hemispherical occlusion); and 4) contact surface area between the cryoballoon and the PV wall (defined as the balloon contact ratio).
RESULTS: Severe PV stenosis (≥75% area reduction) was observed in 9 (1.3%) PVs (6 left superior and 3 right superior PVs) in 9 patients. The PV size, cryoballoon application number and time, minimum freezing temperature, and the depth of cryoballoon position were not significantly associated with occurrence of severe PV stenosis, but the PV angle was significantly smaller in PVs with severe stenosis than it was in those without stenosis (25.6 ± 9.7° vs. 34.2 ± 6.4°; p < 0.001). Hemispherical occlusion was more frequently observed and balloon contact ratio was larger in PVs with severe stenosis (55.6% vs. 14.8%; p = 0.049) than in those without stenosis (0.70 ± 0.06 vs. 0.54 ± 0.08; p < 0.001).
CONCLUSIONS: A horizontally connecting PV, noncoaxial placement of cryoballoon, and a larger contact surface area of the cryoballoon were predictors of the occurrence of severe PV stenosis after cryoballoon ablation.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atrial fibrillation; cryoballoon ablation; pulmonary vein isolation; pulmonary vein stenosis

Year:  2019        PMID: 31753437     DOI: 10.1016/j.jacep.2019.08.003

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  4 in total

Review 1.  [Practical guide for safe and efficient cryoballoon ablation for atrial fibrillation : Practical procedure, tips and tricks].

Authors:  Julian Chun; Tilman Maurer; Andreas Rillig; Stefano Bordignon; Leon Iden; Sonia Busch; Daniel Steven; Roland R Tilz; Dong-In Shin; Heidi Estner; Felix Bourier; David Duncker; Philipp Sommer; Nils-Christian Ewertsen; Henning Jansen; Victoria Johnson; Livio Bertagnolli; Till Althoff; Andreas Metzner
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-11-04

2.  Drug-coated balloon angioplasty for severe pulmonary vein stenosis resulting from cryoballoon ablation for atrial fibrillation.

Authors:  Koji Yamaguchi; Tetsuzo Wakatsuki; Tomomi Matsuura; Kazuhisa Matsumoto; Yutaka Kawabata; Muneyuki Kadota; Kenya Kusunose; Takayuki Ise; Shusuke Yagi; Daiju Fukuda; Hirotsugu Yamada; Takeshi Soeki; Masataka Sata
Journal:  J Cardiol Cases       Date:  2022-03-29

3.  Characteristics of anatomical difficulty for cryoballoon ablation: insights from CT.

Authors:  Takahiro Hayashi; Masato Murakami; Shigeru Saito; Kiyotaka Iwasaki
Journal:  Open Heart       Date:  2022-01

4.  Supplemental Radiofrequency Ablation After Acutely Unsuccessful Cryoballoon Pulmonary Vein Isolation is Associated With Increased Risk of Recurrent Atrial Fibrillation.

Authors:  Henry D Huang; Grzegorz Pietrasik; Qurrat-Ul-Ain Abid; Parikshit S Sharma; Kousik Krishnan; Timothy R Larsen; Richard G Trohman
Journal:  J Am Heart Assoc       Date:  2020-05-12       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.